AngioDynamics (ANGO) Analysts Target $20, Suggesting +41% Upside from Recent Levels
Key Takeaways
- The central $20 price target is the arithmetic mean of four verified analyst targets, which span a wide range from $17 to $24.
- At a recent close near $14.19, reaching $20 would require a gain of roughly 41%, a substantial move.
- Bullish analysts point to NanoKnife adoption in prostate ablation, a newly effective CPT reimbursement code, and above-expectations guidance.
- The company remains unprofitable on a GAAP (Generally Accepted Accounting Principles) basis, with negative EPS (earnings per share), which is a key source of risk.
- Reaching the target likely hinges on sustained NanoKnife procedural growth, reimbursement decisions, and progress toward profitability.
Understanding the Analyst Consensus on ANGO
AngioDynamics, Inc. (ANGO) is a Latham, New York-based medical device maker focused on vascular access, oncology, and thrombus management. Four current analyst price targets were reviewed, ranging from $17 to $24, with an average of $20. That figure is used as the central target here.
The views differ meaningfully. Canaccord Genuity raised its target to $20 from $16 in August 2026, citing a strong close to fiscal 2026 and guidance ahead of expectations, driven by the NanoKnife business. H.C. Wainwright's Yi Chen lifted its target to $19 from $16, highlighting building NanoKnife reimbursement. Lake Street's Frank Takkinen holds the highest target at $24, while Freedom Broker carries a more cautious $17. The spread reflects genuine disagreement about how quickly NanoKnife adoption and profitability will scale. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently closed near $14.19, within a 52-week range of roughly $9.39 to $16.29. A move to $20 implies about 41% upside, a substantial appreciation that would require not just a return to prior highs but a decisive breakout above them.
AngioDynamics operates through Med Tech (including Auryon, the thrombus management platform, and NanoKnife) and Med Device segments. NanoKnife, an irreversible electroporation system cleared for prostate tissue ablation, is the central growth story. A CPT Category I reimbursement code took effect in January 2026, a catalyst analysts cite as supporting procedure volume and revenue growth.
What Could Support a Move Toward the Target
- NanoKnife momentum: Fiscal Q4 revenue rose about 8% year over year to roughly $86.6 million, and NanoKnife growth has been a primary driver.
- Reimbursement tailwind: The CPT Category I code for prostate ablation, effective January 2026, removes a key reimbursement barrier, with a pancreatic cancer code expected in January 2027.
- Raised guidance: Management increased fiscal 2026 adjusted EPS and sales outlooks ahead of expectations, supporting recent target increases.
- Clean balance sheet: The company carries minimal debt and substantial cash, providing flexibility to fund growth.
What Could Prevent the Target From Being Reached
- Persistent losses: The company reports negative GAAP EPS, and valuation remains a concern until profitability improves.
- Reimbursement dependency: NanoKnife adoption partly depends on decisions by Medicare Administrative Contractors (MACs), which could lag expectations.
- Slowing legacy businesses: Some segments, such as parts of the thrombus management franchise, have shown year-over-year declines.
- Execution risk: A leadership transition is expected during the first half of fiscal 2027, adding uncertainty to the turnaround.
- Valuation and sentiment: As a small-cap with negative earnings, the stock can compress quickly if growth disappoints.
Technical Levels and Market Structure
The stock trades near the upper end of its 52-week range, with resistance around the $16 to $16.29 zone at the prior high. A sustained move toward $20 would require clearing that resistance. On the downside, support appears near the long-term moving average in the $12 to $13 area, with the 52-week low near $9.39 as a deeper floor. The long-term trend improved over the past year, but the path to $20 depends on maintaining that uptrend. From what I see, monitoring these levels closely helps frame realistic expectations.
Time Horizon and What Investors Should Monitor
Analyst targets typically reflect a roughly 12-month horizon, though individual assumptions vary. Investors should watch NanoKnife procedure volumes and probe sales, MAC reimbursement determinations, the planned CEO transition, and any updates to adjusted EPS and revenue guidance. Quarterly earnings, particularly commentary on prostate and pancreatic ablation adoption, are the most direct catalysts for the target. I’m watching this closely as reimbursement updates roll in.
Using Tickeron’s AI Daily Buy/Sell Signals
In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful way to track momentum shifts in names like this. The tool monitors thousands of stocks in real time and flags Buy, Sell, or Hold ideas based on technical and AI-driven factors, which can help surface changes in sentiment without manual screening.
Final Assessment
The $20 central target reflects the average of four analyst targets spanning $17 to $24, implying a substantial move of roughly 41% from recent levels. The strongest support comes from NanoKnife growth and a new reimbursement code, while the principal obstacles are persistent losses, reimbursement uncertainty, and execution risk around a leadership transition. Analyst disagreement is real, with targets divided between conservative and aggressive adoption scenarios. Whether the shares can reach $20 depends on sustained procedural growth and progress toward profitability, which upcoming earnings and reimbursement decisions will help clarify.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANGO in downward trend: 10-day moving average broke below 50-day moving average on October 05, 2026
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 66 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ANGO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 201 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 126 of 179 cases where ANGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ANGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.826) is normal, around the industry mean (5.020). P/E Ratio (44.843) is within average values for comparable stocks, (166.342). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther
Advertisement